RECTAL MEASURE SPECIFICATIONS

Cancer Programs Practice Profile Reports (*CP^{3}R*)

Introduction

The Commission on Cancer's (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve the transparency with which the measures in the CP^{3}R and RQRS reporting systems are calculated. To this end, for each measure, supporting information, three tables and a flow-diagram are provided:

- The measure type, clinical rationale and references are provided.
- The ***Measure Item List*** table provides each cancer registy data item used in the assessment of the indicated measure. This includes the FORDS data item name, the North American Association of Central Cancer Registry (NAACCR) item number and a brief description of each item.
- The ***Case Eligibility Criteria*** table itemizes the steps taken to determine whether cases belong in the measure denominator for cases diagnosed 2010 and later. Each condition is described and is accompanied by the data item and code values used in the assesment.
- The ***Numerator Criteria*** table illustrates how cases are assessed to determine whether they qualify for the numerator of the measure, in other words are concordant for the standard of care.
- A **flow-diagram** is provided to illustrate the steps through which cases pass as they are evaluted for the indicated measure. The number appearing in each flow-diagram element corresponds to the assessment criteria appearing in the *Case Eligibility Criteria* and *Numerator Criteria* tables.

Measure Descriptions

This document provides specifications for the following measures:

Measure	Measure Abbreviation	Measure Type
Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer	RECRTCT	Quality Improvement

Note: Newly adopted measures will be integrated into CP^{3}R prior to their release in RQRS.

Measure Type

There are several types of measures approved by the CoC. Evidence-based measures or **accountability** measures promote improvements in care delivery and are the highest standard for measurement. These

measures demonstrate provider accountability, influence payment for services and promote transparency. The **quality improvement** measure function is to monitor the need for quality improvement or remediation. Generally, these measures are for individual program use. **Surveillance** measures are used to identify the status quo, generate information for decision making, and/or to monitor patterns and trends of care. The following Table summarizes the purposes and use of these measures:

Measure Type	Measure definition and use
Accountability	High level of evidence supports the measure, including multiple randomized control trials. These measures can be used for such purposes as public reporting, payment incentive programs, and the selection of providers by consumers, health plans, or purchasers.
Quality Improvement	Evidence from experimental studies, not randomized control trials supports the measure. These are intended for internal monitoring of performance within an organization.
Surveillance	Limited evidence exist that supports the measure or the measure is used for informative purposes to accredited programs. These measures can be used for to identify the status quo as well as monitor patterns and trends of care in order to guide decision-making and resource allocation.

RECRTCT - Rectum Measure: Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer

Measure Type: Quality Improvement

Measure Item List		
FORDS Data Item	**NAACCR #**	**Description**
Primary Site	400	Organ of origin of the cancer
Sex	220	Sex of patient
Age at Diagnosis	230	Age of patient at diagnosis
Sequence Number	560	Sequence of malignant and nonmalignant neoplasms over the lifetime
Histology	522	Microscopic or cellular anatomy of the cancer
Behavior Code	523	Neoplastic behavior of the cancer
Class of Case	610	Indicates the reporting facility's role in managing the cancer
Clinical T	940	AJCC Clinical T
Clinical N	950	AJCC Clinical N
Clinical M	960	AJCC Clinical M
Pathologic T	880	AJCC Pathologic T
Pathologic N	890	AJCC Pathologic N
Pathologic M	900	AJCC Pathologic M
Clinical Stage Group	970	AJCC Clinical Stage Group
Pathologic Stage Group	910	AJCC Pathologic Stage Group

Surgical Procedure of the Primary Site	1290	Surgical procedure of the primary site performed at any facility
Vital Status	1760	Vital Status of the patient as of the date entered in Date of Last Contact
Date of Last Contact or Death	1750	Date of last contact with the patient or the date of death
Date of Initial Diagnosis	390	Date of Initial Diagnosis by a physician for the tumor being reported
Date of Most Definitive Surgical Resection	3170	Date of the most definitive surgical procedure of the primary site
Chemotherapy	1390	The type of chemotherapy administered as first course of treatment at any facility
Date Chemotherapy Started	1220	Date of the initiation of chemotherapy that is part of the first course of treatment
Regional Treatment Modality	1570	Dominant Modality of radiation therapy used to deliver the most clinically significant regional dose
Reason for No Radiation	1430	Reason that no regional radiation therapy was administered to the patient
Date Radiation Started	1210	The date on which radiation therapy began at any facility

RECRTCT - Rectum Measure: Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer

Case Eligibility Criteria			
Diagram Reference	**Assessment**	**FORDS Item**	**FORDS Codes**
1	Primary Site - Rectum	Primary Site	C209
2	Exclude manually censored cases	Exclusion *(This is a user field in CP^{3}R, it is not a FORDS*	Exclude: 80 - Patient enrolled in a clinical trial that directly impacts delivery of the standard of care
3	Male or female	Sex	1, 2
4	Adult patient under the age of 80 at diagnosis	Age at Diagnosis	018-79
5	First or only diagnosis of malignant neoplasm	Sequence Number	00 or 01
6	Stageable Rectum Histologies	Histology	8000-8152, 8154-8231, 8243-8245, 8247-8248, 8250-8576, 8940-8950, 8980-8981
7	Invasive tumors	Behavior Code	3
8	**Stage II-III by Clinical** TNM AJCC 7th ed. (cT3,4N0M0 or cN+M0) or, if TNM is missing Clinical Stage Group (2-3)	Clinical T Clinical N Clinical M Pathologic M Clinical Stage Group	Stage IIA by Clinical TNM (cT3, N0, M0) ***OR*** Stage IIB by Clinical TNM (cT4A, N0, M0) ***OR*** Stage IIC by Clinical TNM (cT4B, N0, M0) ***OR*** Stage IIIA by Clinical TNM (cT1, cT2, & N1, N1A, N1B, N1C, M0 or (cT1, N2A, M0)) ***OR*** Stage IIIB by Clinical TNM (cT3, cT4A, & N1, N1A, N1B, N1C, M0 or cT2, cT3, N2A, M0 or cT1, cT2, & N2B, M0) ***OR*** Stage IIIC by Clinical TNM (cT4A, N2A, M0 or cT3, cT4A & N2B, M0 or cT4B, & N1, N1A, N1B, N1C, N2, N2A, N2B, M0) ***OR*** Clinical Stage Group = 2, 2A, 2B, 2C, 3, 3A, 3B, 3C (Exclude metastatic cases cM/pM = 1, 1A, 1B) (missing cM/pM = cM0/pM0)
	OR		***OR***

RECRTCT - Rectum Measure: Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer

	OR		***OR***
9	For **Stage I by Clinical** TNM AJCC 7th ed. (cT1,2N0M0) or if TNM is missing by Clinical Stage Group, select cases with **Stage II-III by pathologic** TNM (pT3,T4N0M0 or pN+M0) or, if TNM is missing, by Pathologic Stage Group	Clinical T Clinical N Clinical M Clinical Stage group Pathologic T Pathologic N Pathologic M Pathologic Stage group	Stage I by Clinical TNM (cT1, cT2, N0, M0) or Clinical Stage Group = 1 ***AND*** [Stage IIA by Pathologic TNM (pT3, N0, M0) ***OR*** Stage IIB by Pathologic TNM (pT4A, N0, M0) ***OR*** Stage IIC by Pathologic TNM (pT4B, N0, M0) ***OR*** Stage IIIA by Pathologic TNM (pT1, pT2, & N1, N1A, N1B, N1C, M0 or (pT1, N2A, M0)) ***OR*** Stage IIIB by Pathologic TNM (pT3, pT4A, & N1, N1A, N1B, N1C, M0 or pT2, pT3, N2A, M0 or pT1, pT2, & N2B, M0) ***OR*** Stage IIIC by Pathologic TNM (pT4A, N2A, M0 or pT3, pT4A & N2B, M0 or pT4B, & N1, N1A, N1B, N1C, N2, N2A, N2B, M0) ***OR*** Pathologic Stage Group = 2, 2A, 2B, 2C, 3, 3A, 3B, 3C]
10	All or part of the first course of treatment was performed at the reporting facility	Class of Case	10, 11, 12, 13, 14, 20, 21, or 22
11	Surgically Treated Cases at any Facility	Surgical Procedure of the Primary Site	30 - 90

RECRTCT - Rectum Measure: Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer

12	Patient was reported living within 180 days from date of diagnosis (for postoperative treatment measure excludes cases who died <180 days after diagnosis with no chemo or no radiation)	Vital Status Date of Initial Diagnosis Date of Last Contact or Death Chemotherapy Regional Treatment Modality	*For Clinical Stage I with pathologic stage II-III (as defined above):* Vital Status = 1 ***OR*** (Chemotherapy = 01, 02, 03 and Regional Treatment Modality = 20-32, 40-43, 50-55, 60-62, 98) ***OR*** # Elapsed days between Dx and Last Contact >180

RECRTCT - Rectum Measure: Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer

Numerator Criteria			
Diagram Reference	**Assessment**	**FORDS Item**	**FORDS Codes**
13	**Numerator 1**: Preoperative chemotherapy and radiation therapy are recommended or administered for patients with Clinical stage II-III, prior to receiving resection for rectal cancer	Chemotherapy Date Chemotherapy Started Date of Most Definitive Surgical Resection Regional Treatment Modality Reason for No Radiation Date Radiation Started	*For Clinical Stage II-III (as defined above by cTNM or Clinical Stage Group):* (Chemotherapy 01, 02, 03 and Date Chemotherapy Started < Date of Most Definitive Surgical Resection), *OR* (Chemotherapy 82, 85, 86, 87, 88) ***AND*** (Regional Treatment Modality 20-32, 40-43, 50-55, 60-62, 98 and Date Radiation Started < Date of Most Definitive Surgical Resection), *OR* (Regional Treatment Modality 00 and Reason for No Radiation 2-7)
	OR		***OR***
14	**Numerator 2**: Postoperative chemotherapy and radiation therapy are recommended or administered within 6 months (180 days) of diagnosis for patients who are both clinical stage I and Pathologic stage II-III, receiving resection for rectal cancer	Chemotherapy Date Chemotherapy Started Date of Most Definitive Surgical Resection Regional Treatment Modality Reason for No Radiation Date Radiation Started Date of Initial Diagnosis	*For Clinical Stage I with Pathologic Stage II-III (as defined above by TNM or Stage Group):* (Chemotherapy 01, 02, 03 and Date Chemotherapy Started >= Date of Most Definitive Surgical Resection and Date Chemotherapy Started - Date of Initial Diagnosis<=180 days), *OR* (Chemotherapy 82, 85, 86, 87, 88) ***AND*** (Regional Treatment Modality 20-32, 40-43, 50-55, 60-62, 98 and Date Radiation Started >= Date of Most Definitive Surgical Resection and Date Radiation Started - Date of Initial Diagnosis<=180 days), *OR* (Regional Treatment Modality 00 and Reason for No Radiation 2-7)
	Total Numerator =		**Numerator 1 (step 13) + Numerator 2 (step 14)**

Notes:

1) The RECRTCT was introduced into CP^3R in March 2015. It replaced the previous rectal RECRT measure.
2) Updates to RECRTCT measure in the September 2015 CP3R release:
    a. Added alert (S) messages for unknown chemo and/or RT. Previously incomplete cases may become non-compliant if not corrected after 180 days from diagnosis.
    b. Also order of evaluation has changed so some cases that had no chemo and were previously marked as incomplete for unknown RT will now be corrected to non-compliant since chemo was not administered.
3) Updates in the November 2015 CP3R release:
    a) Allow for manual exclusion with censor 80

RECRTCT - Rectum Measure: Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer

RECRTCT - Rectum Measure: Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer



RECRTCT - Rectum Measure: Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or Postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer